Evaxion Biotech A/S ADR (EVAX)’s stock has witnessed a price hike of 8.83% from the previous close with its current price standing at $3.08. Its current price is -77.37% under its 52-week high of $13.61 and 36.28% more than its 52-week low of $2.26. Based on the past 30-day period, the stock price is -14.93% below the high and +8.57% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, EVAX’s SMA-200 is $4.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Additionally, it is important to take into account EVAX stock ratios, including its price-to-sales ratio, which is 59.51 for the last tewlve months.EVAX’s price to book ratio for the most recent quarter was 13.30, resulting in an 2.09 price to cash per share for the period.
How does Evaxion Biotech A/S ADR (EVAX) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 2 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 5.00 in simple terms.
Evaxion Biotech A/S ADR (EVAX): Earnings History
If we examine Evaxion Biotech A/S ADR’s recent earnings history, in the last quarter ended on 6/30/2024, it posted adjusted earnings per share of -$0.12, slashing the consensus of -$0.39. In other words, it beat the consensus by $0.27, resulting in a 69.20% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2024, the stock recorded adjusted earnings per share of -$0.12 in contrast with the Outlook of -$0.39. That was a difference of $0.27 and a surprise of 69.20%.
Evaxion Biotech A/S ADR (EVAX): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 1 different analysts, who are expecting earnings to fall in between the range of -0.12 and -0.12 with an average Earnings Estimate of -0.12 which is in contrast with the last year earnings estimate of -2.10 and also replicates 94.29% growth rate year over year.
Evaxion Biotech A/S ADR (NASDAQ: EVAX) Ownership Details
I will give a breakdown of the key shareholders in Evaxion Biotech A/S ADR (EVAX). Recent figures show that the company’s insiders hold 15.52% of shares. A total of 8 institutional investors hold shares in the company, making 8.26% of its stock and 9.77% of its float.
Jun 30, 2024, it was reported that the Company’s largest institutional holder is Armistice Capital, LLC holding total of 392.0 shares that make 7.03% of the company’s total number of shares and are currently priced at 1.14 million.
The securities firm Invst, LLC holds 54.0 shares of EVAX, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.97%, and the holding percentage of shares is valued at 0.16 million.
An overview of Evaxion Biotech A/S ADR’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Evaxion Biotech A/S ADR (EVAX) traded 78,484 shares per day, with a moving average of $3.13 and price change of +0.01. With the moving average of $2.98 and a price change of +0.13, about 47,553 shares changed hands on average over the past 50 days. Finally, EVAX’s 100-day average volume is 45,463 shares, alongside a moving average of $3.17 and a price change of -0.93.
